ArticleInfection and drug resistance2022
Clinical Features of Pulmonary Nocardiosis in Patients with Different Underlying Diseases: A Case Series Study.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- Clinical patterns, species-specific correlations, and therapeutic outcomes of nocardiosis in immunocompetent individuals: a systematic analysis based on literature.Annals of clinical microbiology and antimicrobials · 2026Pooled it
- The species distribution and antimicrobial resistance profiles of Nocardia species in China: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2023Pooled it
- Successful Treatment with Surgical Resection for Nocardia cyriacigeorgica Infection in Pulmonary Sequestration.Internal medicine (Tokyo, Japan) · 2026Article
- Clinical features of pulmonary nocardiosis: a descriptive research study.BMC pulmonary medicine · 2026Article
- Clinical characteristics of pulmonary nocardiosis in patients with and without bronchiectasis: a single-center retrospective comparative study.Frontiers in cellular and infection microbiology · 2026Article
- Pulmonary nocardiosis: Α threat in the near future for immunocompetent individuals?Lung India : official organ of Indian Chest Society · 2025Article
- Diagnostic Approach to Pneumonia in Immunocompromised Hosts.Journal of clinical medicine · 2025Review
- Clinical characteristics and outcome analysis of pulmonary nocardiosis in southern China: a two-center retrospective study.BMC infectious diseases · 2024Article
- Case report: From oral infection to life-threatening pneumonia: clinical considerations in Nocardia infection from a case.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical features of pulmonary nocardiosis (PN) in patients with different underlying diseases. Methods: Clinical, imaging, treatment and prognosis data from patients diagnosed with PN from July 2011 to June 2021 at the First Affiliated Hospital, Zhejiang University School of Medicine were collected and analyzed. According to different underlying diseases, patients were grouped into immunocompromised host (ICH) group and immunocompetent host (ICO) group, and clinical characteristics were compared between the two groups. Results: There were 64 patients with PN, including 42 males, aged from 21 to 86 (57.1 ± 15.7) years. The most common clinical manifestations were cough, expectoration, fever. There were 41 cases in the ICH group and 23 cases in the ICO group. There were 11 cases with underlying pulmonary diseases in the ICH group, including 2 cases of bronchiectasis, 4 cases of chronic obstructive pulmonary disease (COPD), etc. There were 11 cases of underlying pulmonary basic diseases in ICO group, including 7 cases of bronchiectasis and COPD, 1 case of bronchiectasis, 1 case of COPD, etc. The proportion of patients with bronchiectasis and COPD in the ICO group was significantly higher (P < 0.05). Extrapulmonary nocardiosis infection occurred in 6 patients of the ICH group. During the period of hospitalization, 87.0% patients in ICO group received SMZ/TMP therapy, 73.2% of patients in ICH group received two drug combination therapy. In the ICH group, mortality at 28 days was 14.6% and 8.7% in the ICO group. Conclusion: PN mainly occurred in ICH patients, but also occurred in the ICO cases to a lesser extent, especially in patients with bronchiectasis and/or COPD. Complicated with extrapulmonary infections mainly occurred in ICH population and combination of two antibiotics was often used in ICH group. The case fatality rates were 14.6% in ICH and 8.7% in ICO cases, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.